文献速递肿瘤 PET/CT核素与放射性配体治疗

多示踪剂PET/CT与液体活检分子标志物的跨四分位比较:AI/ML驱动个体化精准诊疗「阶梯式照护」模型的未来展望

Inter- and intra-quartile comparison of multi-tracer PET/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a "stepped care" model for individualized precision theranostics through AI/ML.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-25

本文从多学科视角阐述核医学、液体活检分子标志物及AI/ML方法如何推动精准肿瘤学中的阶梯式照护模型。作者强调核医学在个体化治疗选择与诊疗决策中日益重要的作用,并提出通过当前及新兴分子谱分析技术在放射性配体治疗、化疗和/或免疫靶向治疗间进行个体化选择,以构建AI/ML时代的阶梯式精准诊疗模型。

要点

  • 核医学、液体活检与AI/ML整合可推动精准肿瘤学阶梯式照护模型的发展。
  • 放射性药物在肿瘤细胞及肿瘤微环境靶点上的治疗应用预计将持续扩展。
  • 基于分子谱分析在放射性配体治疗、化疗与免疫治疗间制定个体化序贯优先列表是关键需求。

核心结论

  • 整合核医学分子影像、液体活检分子标志物与AI/ML方法,有助于构建以选择最适肿瘤靶点和循证个体化药物序贯优先列表为基础的阶梯式精准诊疗模型,从而在最小毒性下优化疗效。

研究设计与样本

  • 本文为多学科视角的论述性通讯,未报告系统检索范围、研究样本或具体研究方法。

主要发现

  • 过去约十五年间核医学诊疗一体化应用呈指数增长,将诊断与治疗融合于简单工作流程平台。
  • 预计未来数年将出现针对癌细胞及肿瘤微环境相关靶点(如癌相关成纤维细胞、新生血管化)的多种治疗性放射性药物。
  • 鉴于治疗性放射性药物耐受性良好且毒性相对较低,其有望成为转移性/晚期疾病中全身治疗的优选替代或夹心联合方案。
  • 近年来靶向化疗、免疫导向治疗和放射性药物等全身靶向治疗手段增强,同一癌症可追溯多个 eligible 靶点。

临床怎么用

  • 在精准肿瘤学实践中,可借助当前及新兴分子谱分析技术,在放射性配体治疗、化疗和/或免疫靶向治疗之间进行个体化治疗选择。
  • 可基于科学依据选择最适肿瘤靶点并规划循证个体化药物序贯优先列表,以构建阶梯式精准诊疗路径。

局限性

  • 本文为视角性通讯,未报告原始研究数据、样本量、效应量或统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This communication provides a multidisciplinary perspective on the contribution of nuclear medicine, liquid biopsy-derived molecular markers, and AI/ML-based approaches to evolve a stepped-care model in precision oncology. The subject is of significance, particularly in the current era of precision medicine, where individualized treatment strategies increasingly require the integration of molecular imaging, molecular profiling, and multidisciplinary decision-making. The authors also emphasize the growing role of nuclear medicine in personalized treatment selection and theranostic decision-making, highlighting the next steps in molecular PET-CT imaging for further evolution of Theranostics. The past decade and a half have witnessed an exponential growth in Theranostic applications of Nuclear Medicine and its evolution as a powerful scientific precision approach, blending "diagnostics" and "therapeutics" in a simple workflow platform. One can foresee an evolution of a number of therapeutic radiopharmaceuticals in the coming years directed towards various targets on cancer cells & associated tumor microenvironment (TME) (e.g. cancer associated fibroblasts, neovascularization) and are likely to develop as preferred substitutes to systemic therapies or "sandwich" combinatorial regimens in metastatic/advanced disease, in view of their well-tolerability and relatively low toxicity. The systemic targeted treatment approaches-such as targeted chemotherapy, immune-directed treatments, and radiopharmaceutical agents-have enhanced in recent years, with a number of eligible targets traceable for the same cancer. Developing a "stepped care" precision theranostic approach-by selecting the most appropriate tumor target(s) and planning an evidence-based individualized drug-sequencing priority list on a scientific basis-is a critical need to enhance clinical outcomes by optimizing treatment efficacy with minimal toxicity. This perspective primarily emphasizes on the personalized therapy choices amongst the targeted radioligand therapy, chemotherapy, and/or immune-targeted treatments through the current and emerging molecular profiling technologies to evolve a stepped care precision theranostic model of cancer care, in an era of AI/ML.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Basu S, Ravada SK, Parghane RV, et al. Inter- and intra-quartile comparison of multi-tracer PET/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a "stepped care" model for individualized precision theranostics through AI/ML. Eur J Nucl Med Mol Imaging. 2026. PMID: 42347936. doi:10.1007/s00259-026-08025-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。